1.49
+0.11(+7.97%)
Currency In USD
| Previous Close | 1.38 |
| Open | 1.44 |
| Day High | 1.49 |
| Day Low | 1.44 |
| 52-Week High | 1.73 |
| 52-Week Low | 0.66 |
| Volume | 193,962 |
| Average Volume | 153,454 |
| Market Cap | 98.16M |
| PE | -1 |
| EPS | -1.49 |
| Moving Average 50 Days | 1.22 |
| Moving Average 200 Days | 1.03 |
| Change | 0.11 |
If you invested $1000 in IO Biotech, Inc. (IOBT) since IPO date, it would be worth $95.21 as of July 03, 2025 at a share price of $1.49. Whereas If you bought $1000 worth of IO Biotech, Inc. (IOBT) shares 3 years ago, it would be worth $334.08 as of July 03, 2025 at a share price of $1.49.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 20, 2025 12:05 PM GMT
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that Mai-Britt Zocca, PhD, the company’
IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025
GlobeNewswire Inc.
Apr 26, 2025 7:05 PM GMT
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that one of its scientific co-founder
IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170
GlobeNewswire Inc.
Apr 25, 2025 5:00 PM GMT
Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage